Allogene Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
ALLO$0.93-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Collaboration revenue - related party | $— | $22 |
| Operating expenses: | ||
| Research and development | 150,152 | 192,299 |
| General and administrative | 56,781 | 65,205 |
| Impairment of long-lived asset | 2,382 | 15,717 |
| Total operating expenses | 209,315 | 273,221 |
| Loss from operations | (209,315) | (273,199) |
| Other income (expense), net: | ||
| Interest and other income, net | 19,289 | 20,153 |
| Interest expense | (1,075) | (181) |
| Other income (expense), net | 215 | (3,920) |
| Total other income (expense), net | 18,429 | 16,052 |
| Loss before income taxes | (190,886) | (257,147) |
| Income tax expense | — | (443) |
| Net loss | (190,886) | (257,590) |
| Other comprehensive loss: | ||
| Net unrealized gain on available-for-sale investments | 358 | 866 |
| Net comprehensive loss | $(190,528) | $(256,724) |
| Net loss per share, basic and diluted | $(0.87) | $(1.32) |
| Weighted-average number of shares used in computing net loss pershare, basic and diluted | 220,622,669 | 194,811,756 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.